Posted by Michael Wonder on 13 Aug 2016
TGA approves Briviact (brivaracetam)
12 August 2016 - The TGA has approved UCB's Briviact (brivaracetam).
Briviact was approved by the TGA on 4 August 2016 for use as add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with epilepsy.
